<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemoprevention and screening in oral dysplasia and squamous cell head and neck cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemoprevention and screening in oral dysplasia and squamous cell head and neck cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chemoprevention and screening in oral dysplasia and squamous cell head and neck cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nabil F Saba, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dong Moon Shin, MD, FACP, AAAS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Brockstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall R Posner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Squamous cell carcinoma of the head and neck (SCCHN) is common in several regions of the world. The primary risk factors include tobacco use, alcohol consumption, and human papillomavirus (HPV) infection. The relative prevalence of these risk factors contributes to the variation in the observed distribution of head and neck cancer in different areas of the world. (See  <a class="medical medical_review" href="/z/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer"</a>.)</p><p>The chronic exposure of the upper aerodigestive tract to these and other risk factors is thought to produce field cancerization, a process in which patients with cancer or premalignant dysplastic lesions in the oral mucosa are at significant risk for head and neck cancer. The understanding of field cancerization provides the rationale for chemoprevention to decrease the incidence of SCCHN.</p><p>The use of chemoprevention to block the progression of precancerous lesions and the potential role of screening are discussed in this topic, focusing primarily on carcinogen-related head and neck cancer.</p><p class="headingAnchor" id="H1095522675"><span class="h1">RATIONALE FOR CHEMOPREVENTION</span><span class="headingEndMark"> — </span>The rationale for pharmacologic chemoprevention in patients at risk for the development of invasive cancer is based on two factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Field cancerization</strong> – Patients with carcinogen-related squamous cell carcinoma of the head and neck (SCCHN) have a predilection for cancer development throughout the oral and oropharyngeal mucosa. Whether this is also true for human papillomavirus (HPV)-associated oropharyngeal tumors is still not well established.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multistep carcinogenesis</strong> – SCCHNs result from a multistep process with defined intermediate stages, leading to fully transformed, invasive, and metastatic cancer [<a href="#rid1">1</a>].</p><p></p><p>Standard options for managing oral dysplasia, a precursor of invasive cancer, range from watchful waiting to biopsy, laser surgery, and aggressive resection. However, none of these approaches has a proven clinical benefit. Other approaches to decreasing the incidence of invasive tumor growth in patients with recognizable premalignant lesions have fallen into several categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of further carcinogenic exposures (eg, tobacco, alcohol, betel nut) [<a href="#rid2">2</a>]. This strategy is important, but it may not be sufficient since many or most of the critical genetic alterations leading to transformation have already occurred in "early" premalignant lesions. (See  <a class="medical medical_review" href="/z/d/html/3387.html" rel="external">"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemoprevention or pharmacologic intervention to reverse or inhibit carcinogenic progression. Chemoprevention can be considered in two settings: primary chemoprevention in individuals with de novo premalignant lesions and secondary chemoprevention in patients who have undergone potentially curative therapy in order to prevent recurrent disease or second primary tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening individuals known to be at high risk for the development of invasive cancer based on the presence of risk factors or premalignant lesions in a target population.</p><p></p><p class="headingAnchor" id="H2"><span class="h2">Field carcinogenesis and chemoprevention</span><span class="headingEndMark"> — </span>Patients with SCCHN due to environmental carcinogens have a global predilection for the development of cancer throughout the oral, pharyngeal, and laryngeal mucosa. The concept of field carcinogenesis was initially proposed in the 1950s [<a href="#rid3">3</a>]. Subsequent studies confirmed that patients with cancer or premalignant dysplastic lesions in the oral mucosa are at significant risk for the development of head and neck cancer at noncontiguous mucosal sites [<a href="#rid4">4,5</a>]. The presence of such a field defect has precluded the routine use of surgical resection of premalignant disease as a curative approach. (See  <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">"Pathology of head and neck neoplasms"</a>.)</p><p>This field defect is attributed to carcinogenic exposure from risk factors (eg, tobacco and alcohol) throughout the entire oropharyngeal mucosa. (See  <a class="medical medical_review" href="/z/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer"</a>.)</p><p>Field carcinogenesis is supported by both epidemiologic and molecular studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Cancer at one site in the head and neck is a strong predictor for the development of a second primary tumor elsewhere [<a href="#rid6">6,7</a>]. Second tumors can either occur at or close to the same time as the primary lesion (synchronous) or six months or more later (metachronous). Synchronous second tumors are often occult lesions in the upper aerodigestive tract discovered during the initial staging evaluation, whereas metachronous second tumors most often involve other sites in the head and neck region or elsewhere in the upper aerodigestive tract (lung, esophagus) [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">"Overview of the diagnosis and staging of head and neck cancer", section on 'Incidence of second and multiple primaries'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Molecular analyses have often demonstrated that first and second lesions are clonally distinct, ruling out locoregional recurrence as a universal explanation [<a href="#rid9">9</a>]. However, in some cases, physically distinct mucosal tumors may share a common origin, suggesting that genetically abnormal precursor cells have the capacity to migrate extensively within the mucosa [<a href="#rid10">10,11</a>]. Histologically normal mucosa in patients with head and neck cancer may contain evidence of genetically abnormal cells at discrete sites not contiguous with the known cancer [<a href="#rid12">12</a>]. This may in large part explain the failure of surgical excision of grossly evident dysplastic lesions to substantially reduce the risk of cancer in patients with premalignant lesions. However, data from The Cancer Genome Atlas (TCGA) have not addressed these molecular abnormalities in premalignant areas because of the lack of available tissues, which needs to be addressed in future studies [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Surrogate markers and potential target agents</span><span class="headingEndMark"> — </span>The goal of chemoprevention is to decrease the number of cancers that develop in the anatomic area at risk. Direct demonstration of a decreased incidence of cancer requires that very large numbers of patients be followed over long periods of time. Thus, there has been interest in defining alternative surrogate endpoints to both evaluate the efficacy of chemopreventive therapies and to serve as molecular prognostic factors for risk stratification in chemoprevention trials.</p><p>The accurate identification of lesions with carcinogenic potential is critical to chemopreventive studies. Grossly evident lesions that may be precancerous include leukoplakia (white plaques) and erythroplakia (red plaques). Standard histologic assessment alone of these lesions lacks adequate specificity and sensitivity [<a href="#rid14">14</a>]. Histologic criteria in noninvasive dysplastic lesions that have been suggested to correlate with progressive carcinogenic potential include the degree of nuclear atypia, failure of organized differentiation, loss of cell-cell contacts, the presence of keratotic bodies, and the cellular DNA content. (See  <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">"Pathology of head and neck neoplasms"</a>.)</p><p>Genetic definitions of progressive premalignant stages are being defined. Histologic progression has been correlated with sequential clonal genomic alterations, including deletions of chromosome arms 3p, 9p, 11q, and 17p [<a href="#rid15">15-17</a>]. A number of tumor suppressor genes thought to be critical in tumorigenesis have been mapped within these regions. (See  <a class="medical medical_review" href="/z/d/html/3387.html" rel="external">"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations"</a>.)</p><p>Many of these genomic alterations have in turn been associated with abnormal expression of a number of proteins that may hold promise as potential intermediate endpoints and molecular prognostic factors for chemoprevention studies. The reversal of molecular alterations that are tightly linked to the development of oral cancer (eg, epidermal growth factor receptor [EGFR] [<a href="#rid18">18</a>], transforming growth factor alpha [TGFA] [<a href="#rid19">19</a>], p53 [<a href="#rid20">20-22</a>], proliferating cell nuclear antigen [PCNA] [<a href="#rid23">23</a>], telomerase [<a href="#rid24">24</a>], and retinoic acid receptor beta [RARB] [<a href="#rid25">25</a>]) might indicate a reduced risk of oral cancer. (See  <a class="medical medical_review" href="/z/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer"</a>.)</p><p>In addition, folate deficiency has also been linked to a higher risk of developing SCCHN [<a href="#rid26">26,27</a>]. A deficiency in folate seems to disrupt gene methylation as well as DNA structure. Genes that may be affected include tumor suppressor genes such as p16 and possibly p53 [<a href="#rid28">28</a>].</p><p>Genetic polymorphisms in folate metabolism have also been associated with clinical characteristics that may increase the risk of SCCHN, such as advanced age, tobacco and alcohol use, and male sex [<a href="#rid29">29</a>].</p><p>Supplemental <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> may be exerting its chemopreventive role by inhibiting proliferation of mucosal epithelium. This process has been associated with a decreased concentration of EGFR in other tumor types, such as colon cancer [<a href="#rid30">30</a>]. In addition, SCCHNs clearly express folate receptors [<a href="#rid31">31</a>]. Furthermore, a pretreatment elevated intake of dietary folate was suggested as an independent prognostic factor for improved clinical outcomes in SCCHN patients [<a href="#rid32">32</a>]. Folate is therefore an interesting natural compound worth exploring in chemopreventive studies of the head and neck.</p><p>Other nutritional compounds of possible interest in chemoprevention include zinc. A mild deficiency of zinc was observed in 25 percent of the normal healthy volunteers and 48 percent of the head and neck cancer subjects, raising the possibility that zinc deficiency might contribute to the development of SCCHN. This has been explained by the possible dysfunction of type 1 T helper (TH1) cells, as evidenced by decreased production of interleukin 2 (IL-2) and interferon gamma in zinc-deficient head and neck cancer patients [<a href="#rid33">33</a>]. There is, however, no clear evidence for a clinical benefit from zinc supplementation in the chemoprevention of SCCHN.</p><p>Despite the interest in <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> as a possible chemopreventive agent [<a href="#rid34">34</a>], there is insufficient evidence to suggest a benefit for selenium supplementation in the prevention or prognosis of SCCHN.</p><p>Studies have suggested that soy supplementation has anticancer properties, and soy has been shown to inhibit carcinogenesis in animal models [<a href="#rid35">35,36</a>]. In addition, Bowman-Birk inhibitor is a protease inhibitor derived from soybeans that has demonstrated chemopreventive activity and has been tested in patients with oral leukoplakia with evidence of clinical benefit in 31 percent of patients [<a href="#rid37">37</a>]. There is, however, no conclusive evidence to support the use of genistein, a soy derivative, to prevent SCCHN or improve its prognosis. Studies investigating the properties of genistein as an antiinflammatory and anticarcinogenic agent in SCCHN are underway.</p><p>At least some data suggest that expression of podoplanin, a lymphatic endothelial marker whose biologic roles are incompletely understood, might be a powerful predictive factor for oral cancer development in patients with leukoplakia [<a href="#rid38">38</a>]. These data were derived from a randomized chemoprevention trial comparing 13-cis-retinoic acid, <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a> plus retinyl palmitate, and retinyl palmitate alone in 163 patients with oral leukoplakia. High levels of podoplanin expression by immunohistochemistry were associated with a significantly higher incidence of oral cancer (five-year risk 37 versus 8 percent in those with podoplanin-negative lesions). Risk could be further stratified by combining histology (the presence or absence of dysplasia) with podoplanin expression.</p><p>Which factors are useful predictors of carcinogenic progression and which molecular abnormalities best predict reduction in subsequent cancer risk when normalized remain unclear. In addition, a complete histologic response in premalignant lesions may be seen following administration of a chemopreventive agent in patients despite the persistence of chromosomal abnormalities [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1055378701"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>We recommend oral cavity cancer screening for squamous cell carcinoma of the head and neck (SCCHN) in all patients, including high-risk groups of alcohol and tobacco users. In a randomized clinical trial, regular screening reduced mortality from oral cavity cancer by approximately 30 percent, likely due to detection of early-stage disease [<a href="#rid39">39,40</a>].</p><p>Oral cancer occurs in sites that are generally accessible by physical examination. Routine mouth examinations prevent SCCHN by detecting premalignant or early malignant lesions in the general population and in high-risk individuals (alcohol and tobacco users) [<a href="#rid41">41-43</a>]. In addition to screening, information and education on the health risks of tobacco should be thoroughly disseminated.</p><p>Population-based studies have demonstrated that a primary care screening strategy for early detection of head and neck cancer reduces overall mortality in the general population and can reach a large number of at-risk individuals [<a href="#rid39">39,40</a>]. In resource-limited countries, screening high-risk individuals could be an effective prevention strategy, although it is not known whether it is cost-effective.</p><p>The challenge with conducting screening studies is in identifying the high-risk group, the appropriate intervention or screening test, the duration of screening initiative, and the health outcome of interest. The quality of a screening program is affected by participation rate, test performance (sensitivity and specificity), frequency of screening, participant compliance, and duration of follow-up of positive test results. </p><p>Data from various screening initiatives in industrialized and resource-limited countries are as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>In India, the Kerala Oral Cancer Screening Trial demonstrated that visual screening of the oral cavity over almost a decade reduced mortality from oral cancer by up to 29 percent, especially in high-risk groups of tobacco and/or alcohol users and despite expected limitations in compliance with screening and subsequent treatment referral. This trial evaluated over 190,000 healthy patients, age 35 years or older without a prior history of oral cancer, in 13 population clusters (municipal administrative units). Patients were randomly assigned either to three rounds of oral visual inspection by trained health workers at three-year intervals (seven clusters of 96,516 patients) or to standard care (six clusters of 95,354 patients) [<a href="#rid39">39,40</a>]. Patients who screened positive for disease were subsequently referred for clinical examination, biopsy, and treatment. At up to nine years of total follow-up, compared with standard care, screening reduced oral cancer mortality by 27 percent in all patients (HR 0.73, 95% CI 0.54-0.98) and by 29 percent in ever-tobacco and/or ever-alcohol users (HR 0.71, 95% CI 0.506-0.995) [<a href="#rid40">40</a>]. The absolute efficacy of screening was also greatest in those predicted to be at the highest risk of developing oral cancer at seven years. The number of screens administered was consistent with expected real-life compliance (3 screens planned versus 1.76 screens received). Similarly, the compliance rate of screen-positive patients with expert referral was also estimated at approximately 67 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Cuba, the Oral Cancer Case Finding Program (OCCFP) was based on health education and thorough examination of the oral cavity by "stomatologists" in specialized stomatology centers [<a href="#rid41">41</a>]. Between 1983 and 1990, over 10 million patients were examined, 30,478 were referred for detected abnormalities, and 8259 complied with their referral. In the last group, 2367 leukoplakias, 853 other precancerous lesions, and 708 malignant neoplasms were diagnosed. The potential efficacy of this program is evident by an increased incidence of stage I oral cancers (from 22 to 48 percent) and the reduced incidence of more-advanced (stages II to IV) cancers (from 77 to 52 percent). However, these health outcome measures are subject to the potential influences of both "length bias" and "lead time bias." A reduction in population mortality would be a more appropriate surrogate measure of the effectiveness of the screening method.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study in the United States, screening for squamous cell carcinomas of the oral cavity, pharynx, and larynx with symptom assessment and systematic inspection of the oral mucosa was performed by primary care practitioners at health care sites serving residents of urban Boston [<a href="#rid43">43</a>]. Of the 4611 tobacco users older than 40 years who were screened, 313 had specific criteria for otolaryngologic referral. The prevalence of oral mucosal lesions and persistent hoarseness was 13 and 11 percent, respectively. Abnormal findings were seen in over 70 percent of referred patients, and cancer was diagnosed in 3 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In studies involving over 250,000 subjects in Sri Lanka, primary health care workers detected a total of 44 new oral cancers. However, mortality was not reduced in these areas, possibly due to poor compliance following initial screening [<a href="#rid42">42</a>].</p><p></p><p>Future screening strategies based on detection of molecular abnormalities (eg, promoter hypermethylation) in body fluids such as serum and saliva may hold some promise, but this technology remains investigational [<a href="#rid44">44-47</a>]. </p><p class="headingAnchor" id="H4"><span class="h1">CHEMOPREVENTION TRIALS</span><span class="headingEndMark"> — </span>No chemopreventive agents have been shown to decrease the incidence of squamous cell carcinoma of the head and neck (SCCHN) in adequately powered randomized clinical trials.</p><p>Patients suitable for a chemoprevention trial may have a documented precancerous lesion or have a known risk factor for developing malignancy without having a premalignant lesion. A third group of patients are those with previously treated malignancy who are at a significant risk for developing a second primary tumor [<a href="#rid48">48</a>].</p><p>So far, chemopreventive trials in SCCHN have been conducted in patients with known premalignant lesions or in those at risk for a second primary tumor. With the observed sharp increase in the incidence of human papilloma virus (HPV)-related oropharynx cancer, a future generation of chemopreventive trials may focus on subjects with a high risk for developing HPV-related oropharyngeal cancer based on known HPV infection, lifestyle, environmental exposure, or a combination of these factors. The challenges facing chemoprevention in this group are the lack of a clearly defined precancerous lesion and the lack of clear risk stratification that would clearly identify the subjects who might benefit [<a href="#rid49">49,50</a>].</p><p>Most of the completed chemoprevention trials for premalignant lesions of the oral cavity and oropharynx have studied either naturally occurring compounds (<a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a>, <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a>) or synthetically derived retinoids. In addition, early phase studies have examined epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX-2) inhibitors as single agents or in combinations [<a href="#rid51">51-53</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Vitamin A, vitamin E, and beta-carotene</span><span class="headingEndMark"> — </span>The interest in the antioxidants <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a>, <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, and <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a> as chemopreventive agents is due to their apparent efficacy in inducing regression of oral leukoplakia. Although these agents have been studied relatively extensively, both for primary and secondary chemoprevention, none has an established role.</p><p class="headingAnchor" id="H1095522983"><span class="h3">Primary chemoprevention</span><span class="headingEndMark"> — </span>Reports on the utility of <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> to treat oral leukoplakia date back to 1957, when a 90 percent response rate was described in 20 patients [<a href="#rid54">54</a>]. Subsequent trials supported the activity of vitamin A in oral leukoplakia in populations likely to be deficient in vitamin A and at risk based on tobacco or betel nut chewing [<a href="#rid55">55,56</a>]. The applicability of these results to disease in relatively developed nations where vitamin deficiency is rare is unclear. High response rates have also been described with the administration of <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a>, a precursor of vitamin A, to patients with oral leukoplakia [<a href="#rid57">57-59</a>]. In one series of 24 patients, for example, there were 15 partial and 2 complete responses with no significant toxicity [<a href="#rid57">57</a>].</p><p>One double-blind placebo-controlled trial has been performed [<a href="#rid60">60</a>]. This study randomized 160 people in India with oral precancerous lesions to <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> (300,000 international units per week), <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a> (360 mg per week), or placebo over a 12-month period. The complete regression rates were 10 percent with placebo, 52 percent with vitamin A, and 33 percent with beta-carotene. No major toxicities were observed. One-half of the responders to beta-carotene and two-thirds of those to vitamin A relapsed after the supplements were discontinued.</p><p>Alpha-tocopherol (<a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>) has also been evaluated for the primary prevention of upper aerodigestive malignancies in patients at risk for head and neck cancer [<a href="#rid61">61,62</a>]. These two placebo-controlled studies, which randomly assigned patients to <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a>, alpha-tocopherol, both, or neither, did not provide any evidence to support a protective effect from these agents.</p><p>These observations provided the rationale for a pivotal randomized placebo-controlled study of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (1 to 2 mg/kg per day) in 44 patients with leukoplakia [<a href="#rid63">63</a>]. This trial included pretreatment and posttreatment histologic evaluation in all patients, permitting analysis of the response among truly dysplastic lesions. After three months of therapy, both the overall clinical response rates (67 versus 10 percent) and the response rates among patients with biopsy-proven dysplasia (54 versus 10 percent) were significantly higher in the actively treated patients.</p><p>However, toxicity was particularly severe in patients dosed at the higher dose of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (2 mg/kg per day), with 47 percent of patients requiring dose reduction. Patients treated at the lower dose level (1 mg/kg per day) had less toxicity and did not require dose reduction, although most noted xeroderma and 29 percent developed conjunctivitis. Furthermore, over 50 percent of responders relapsed within three months of treatment cessation. </p><p>In a second trial, 70 patients with leukoplakia underwent induction with high-dose <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (1.5 mg/kg per day for three months) and were then randomized to "maintenance" with low-dose isotretinoin (0.5 mg/kg per day for nine months) or <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a> (30 mg/day) [<a href="#rid64">64</a>]. Of the 53 evaluable patients, a response to maintenance therapy or continuation of stable lesions was significantly more common with isotretinoin (92 versus 45 percent, p&lt;0.001). Side effects were generally mild but were more prominent with isotretinoin.</p><p class="headingAnchor" id="H1095522991"><span class="h3">Secondary chemoprevention</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">Beta-carotene</a> and alpha-tocopherol (<a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>) have been evaluated as secondary chemopreventive agents in patients with head and neck cancer [<a href="#rid65">65</a>]. No evidence of benefit has been observed, while a possible detrimental effect of supplementation with beta-carotene plus alpha-tocopherol was suggested in a secondary prevention trial in which 540 patients undergoing radiation therapy for stage I or II head and neck cancer were randomly assigned to both agents or placebo for three years starting the first day of radiation [<a href="#rid65">65</a>]. Beta-carotene supplementation was discontinued after 156 patients were enrolled because of ethical concerns. After a median follow-up of 52 months, alpha-tocopherol-supplemented patients had a significantly higher rate of tumor recurrence or second primary cancer (hazard ratio [HR] 1.86, 95% CI 1.27-2.72) during the supplementation period, which decreased thereafter.</p><p>Retinoid therapy has been evaluated as a secondary chemopreventive after surgery or radiation for localized head and neck cancer to prevent recurrence of the original primary or development of a second primary [<a href="#rid65">65-71</a>]. These trials have failed to demonstrate any consistent evidence of clinical benefit.</p><p>As an example, in the largest trial, 1190 patients were randomly assigned to <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> 30 mg daily or placebo after treatment for stage I or II head and neck cancer [<a href="#rid70">70</a>]. Isotretinoin provided no significant benefit in terms of time to develop a second primary tumor, rate of second primary tumors, overall survival, or recurrence-free survival. Only one much smaller trial, which used relatively high doses of isotretinoin and included only 103 patients, suggested a decrease in the incidence of secondary cancers [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Synthetic retinoids</span><span class="headingEndMark"> — </span>The most extensively studied compounds for premalignant oropharyngeal disease are the synthetic retinoids [<a href="#rid66">66,67,72-74</a>]. These studies examined the utility of three retinoids: <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (13-cis-retinoic acid), all-trans-retinoic acid, and etretinate; all were active, with overall response rates of 59 to 92 percent. Despite these observed responses, a major limitation to the agents is the retinoid-related toxicity. The newer generations of receptor-selective retinoids may help in overcoming this limitation [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H346511309"><span class="h3">Mechanism of action</span><span class="headingEndMark"> — </span>The mechanism by which retinoids affect premalignant lesions has not been fully elucidated. Many premalignant dysplastic lesions (60 percent in one series compared with none in normal specimens) express very low levels of the nuclear retinoid receptor beta (RAR beta), a component of several bipartite transcription factors responsive to retinoic acid [<a href="#rid76">76</a>]. This deficiency is reversed with retinoid therapy, which may reestablish many aspects of normal growth and differentiation in the aberrantly proliferating premalignant clone [<a href="#rid76">76,77</a>]. In one study of patients with premalignant lesions, the highest response rate (70 percent) was noted in patients with low baseline expression of the tumor suppressor p53 protein and upregulation of RAR beta messenger RNA after <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid77">77</a>]. Retinoids also have antiangiogenic activity, which may directly or indirectly contribute to their antineoplastic activity [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H1055378747"><span class="h2">Cyclooxygenase 2 inhibitors</span></p><p class="headingAnchor" id="H1055378769"><span class="h3">Nonsteroidal antiinflammatory drug therapy</span><span class="headingEndMark"> — </span>Intake of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and other nonsteroidal antiinflammatory drugs (NSAIDs) prevents the development of intraepithelial neoplasia in the colon and rectum. The mechanism of this chemopreventive effect is thought to be inhibition COX-2 and diminished synthesis of prostaglandins, which are overproduced in colorectal tumors and have been implicated in tumorigenesis. (See  <a class="medical medical_review" href="/z/d/html/2600.html" rel="external">"NSAIDs (including aspirin): Role in prevention of colorectal cancer"</a>.)</p><p>A similar rationale has been applied to the study of NSAIDs as chemopreventive agents for head and neck cancer, since both premalignant and malignant lesions of the oral cavity overexpress COX-2 [<a href="#rid79">79,80</a>]. In addition, administration of NSAIDs to laboratory animals prevents oral cancer development [<a href="#rid81">81,82</a>].</p><p>Results from randomized trials are not available, and the results of case-control and cohort studies are conflicting:</p><p class="bulletIndent1"><span class="glyph">●</span>A possible protective effect of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> use on the development of head and neck cancer was suggested in a questionnaire-based case-control study of 529 head and neck cancer patients and 529 hospital-based controls matched for age, sex, and smoking status [<a href="#rid83">83</a>]. Compared with never users, aspirin use was associated with a significant 25 percent reduction in the risk of head and neck cancer, and there was a trend toward greater risk reduction with increasing duration of use. When analyzed by smoking and alcohol exposure levels, participants exposed to heavy smoking and alcohol use did not appear to benefit from the protective effect of aspirin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population-based cohort study from Denmark failed to find evidence that NSAIDs protect against oral cancer [<a href="#rid84">84</a>]. However, the study did not control for tobacco or alcohol use and considered only prescription use of NSAIDs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A case-control study reported a protective effect of NSAID intake on the risk of head and neck cancer in tobacco users [<a href="#rid85">85</a>] but was later retracted because of concerns over data fabrication [<a href="#rid86">86</a>].</p><p></p><p>Long-term ingestion of NSAIDs may be limited by toxicity. A novel approach, topical application, was used in a double-blind trial in which 57 patients with oropharyngeal leukoplakia were randomly assigned (in a 2:1 ratio) to a 30 second, twice daily rinse with <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a> (0.1 percent solution) or placebo [<a href="#rid87">87</a>]. Compared with controls, the treated group did not have a greater objective decrease in the size of the leukoplakia lesions (which were bidimensionally measured at days 0 and 90) or in their histologic appearance.</p><p>Since surrogate markers of exposure in the oral cavity (eg, prostaglandin E2 inhibition) were not studied, it is difficult to ascertain whether this negative result reflects ineffective delivery of the chemopreventive agent to the oral epithelial cells or an incorrect hypothesis.</p><p>A large body of laboratory investigations supports the use of COX-2 inhibitors in treating several cancers [<a href="#rid88">88-90</a>], including SCCHN [<a href="#rid91">91-94</a>]. COX-2 plays a role in the carcinogenesis of epithelial tumors by influencing key processes, such as apoptosis, angiogenesis, and proliferation, as well as invasion and metastasis [<a href="#rid89">89</a>]. In SCCHN the expression of COX-2 is noted by western blot analysis in the mucosa of subjects at different stages of carcinogenesis, unlike in the normal mucosa [<a href="#rid95">95</a>]. COX-2 is also expressed in early and intermediate stages of carcinogenesis with progressively increased expression throughout all of these stages, further supporting the role it may play in the carcinogenesis process and lending support to the rationale for using COX-2 inhibitors in SCCHN chemoprevention [<a href="#rid94">94</a>].</p><p>The evidence from earlier studies that NSAIDs may delay the growth of head and neck tumor cell lines [<a href="#rid96">96-98</a>] has led to the use of COX-2 inhibitors as single agents in patients with dysplasia [<a href="#rid99">99</a>].</p><p>The use of COX-2 inhibitors was, however, associated with a small but significant increase in the incidence of cardiovascular complications in some placebo-controlled trials [<a href="#rid100">100,101</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Epidermal growth factor receptor inhibition</span><span class="headingEndMark"> — </span>EGFR is highly expressed in SCCHN [<a href="#rid18">18,102</a>] as well as a wide variety of other tumors (eg, colon, non-small cell lung, breast, kidney, head and neck, bladder, and ovarian cancers) [<a href="#rid103">103-105</a>]. However, data are limited on the efficacy of EGFR inhibitors such as <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> [<a href="#rid106">106</a>] or <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> [<a href="#rid107">107</a>]. </p><p><a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">Erlotinib</a> did not demonstrate efficacy as a chemoprevention agent for SCCHN in one phase III randomized trial [<a href="#rid107">107</a>]. In the chemoprevention study Erlotinib Prevention of Oral Cancer (EPOC), 150 patients with documented oral leukoplakia (ie, oral premalignant lesions) and high-risk loss of heterozygosity (LOH) profiles were randomly assigned to either erlotinib or placebo for one year, followed by observation for the development of cancer. Patients with a high-risk LOH profile included either those without cancer but with LOH in 3p and/or 9p and one other specific chromosomal locus, or those with curatively treated oral cancer and LOH in 3p and/or 9p. After a median follow-up of three years, the cancer-free survival rates were similar between those treated with erlotinib and those treated with placebo (74 versus 70 percent, HR 1.27, 95% CI 0.68-2.38).</p><p>Molecular profiling of premalignant oral cavity lesions remains an active area of investigation. In the <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> chemoprevention study discussed above, LOH was validated as a marker of oral cancer risk and was associated with increased EGFR copy numbers [<a href="#rid107">107</a>]. Another separate analysis demonstrated an association with the development of oral cancer in oral precancers with select molecular features (eg, high tumor mutation burden, <em>TP53 </em>mutations, and a specific 12-gene RNA signature) [<a href="#rid108">108</a>]. </p><p class="headingAnchor" id="H1055378939"><span class="h2">Combined inhibition of epidermal growth factor receptor and cyclooxygenase 2</span><span class="headingEndMark"> — </span>The interaction between the EGFR and COX-2 pathways has been extensively investigated in preclinical as well as clinical studies, with evidence that targeting these two pathways can synergistically or additively reverse the progression of SCCHN [<a href="#rid109">109,110</a>].</p><p>These observations provided the rationale for using the combination of EGFR and COX-2 inhibitors in SCCHN chemoprevention trials.</p><p>In one such study, the maximum tolerated dose of <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> in combination with <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a> at 400 mg twice daily was 50 mg/day; skin rash was the main toxicity. Even though the small number of patients limited the ability to draw conclusions, the reversal of dysplasia to a lower grade was reported to be 63 percent (complete response 43 percent, partial response 14 percent, stable disease 29 percent, disease progression 14 percent) and response to therapy was correlated with downregulation of EGFR and phospho-ERK in serial biopsies, suggesting the possible utility of these markers as surrogate endpoints for response [<a href="#rid51">51,52</a>].</p><p>Since tumorigenesis has been associated with the activation of the mammalian (mechanistic) target of rapamycin (mTOR) pathway, there has been interest in exploring mTOR inhibitors as possible effective chemopreventive agents in SCCHN [<a href="#rid111">111</a>]. Interestingly, the combined chemopreventive effect of <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a> and <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> seemed to exert some modulation on the mTOR pathway [<a href="#rid52">52</a>]. Though worth exploring, mTOR inhibitors have not reached clinical applications in SCCHN chemoprevention. </p><p class="headingAnchor" id="H11"><span class="h2">Natural compounds</span><span class="headingEndMark"> — </span>An array of natural compounds, such as green tea extract, curcumins, resveratrol, luteolin, pomegranate juice, and soybeans, is under investigation in head and neck chemoprevention trials. These compounds contain high levels of polyphenols, which have antioxidant properties and inhibit carcinogenesis mediated by downstream signaling pathways [<a href="#rid37">37,112-114</a>]. Dietary intake of certain nutrients (vitamin C, carotene, <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>) has also been inversely linked to the incidence of oral and pharyngeal cancers [<a href="#rid115">115</a>].</p><p>There is limited evidence for the efficacy of increased consumption of green tea and its associated derivatives, either alone or in combination with targeted agents (eg, <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>) for chemoprevention of SCCHN. Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Green tea, which contains polyphenols, may have anticancer properties based on preclinical studies and an early phase clinical trial [<a href="#rid116">116-119</a>]. As an example, the combination of green tea polyphenon E (PPE) 200 mg three times a day and <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> 100 mg daily was evaluated in a phase 1 trial in patients with advanced premalignant lesions of the head and neck; a majority had severe dysplasia. In this study, the pathologic complete response rate was 47 percent and the regimen was well tolerated, suggesting its possible application in further clinical trials [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another main ingredient found in green tea extracts, epigallocatechin gallate (EGCG), has also been linked to modulation of the signaling pathways that play a key role in the carcinogenesis process. EGCG also seems to have a synergistic or additive effect when combined with other natural compounds, such as lycopene [<a href="#rid121">121,122</a>]. In preclinical studies, EGCG also demonstrated synergistic activity on cancer cells in combination with the EGFR tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> [<a href="#rid123">123</a>]. Further clinical studies are needed to validate these results.</p><p></p><p class="headingAnchor" id="H826411826"><span class="h2">Immunotherapy</span><span class="headingEndMark"> — </span>Checkpoint inhibitor immunotherapy may have a possible role in primary chemoprevention of SCCHN, and further clinical trials are needed. The potential efficacy of programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors for primary chemoprevention is suggested by the existence of an initial immune-privileged site after initial viral HPV infection [<a href="#rid124">124</a>] and the established activity of immunotherapy in those with advanced or metastatic HNSCC, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer"</a>.)</p><p class="headingAnchor" id="H1055378960"><span class="h2">HPV-related oropharyngeal carcinoma</span><span class="headingEndMark"> — </span>Human papillomavirus (HPV) 16 is an important risk factor for the development of oropharyngeal cancer and is responsible for the increased incidence of this disease. (See  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Epidemiology'</a>.)</p><p>The E6 and E7 HPV viral proteins in HPV 16 are responsible for promoting cell cycle progression and viral DNA replication in differentiated normal mucosal epithelial cells. While E6 protein binds to p53 tumor suppressor protein and induces its degradation, the E7 protein ubiquitinates the retinoblastoma tumor suppressor protein. This process leads to driving the mucosal cells into S phase and induces cellular DNA synthesis [<a href="#rid125">125,126</a>].</p><p>Studies using oral rinses and polymerase chain reaction (PCR) for HPV DNA have identified 7 percent of the adult population with active oral HPV infection, but only approximately 3 percent of males and 1 percent of females have high-risk HPV infection [<a href="#rid127">127</a>], and this group could form a target for chemoprevention. </p><p class="headingAnchor" id="H1055378966"><span class="h2">Prevention of HPV-related oropharyngeal carcinoma</span><span class="headingEndMark"> — </span>The improvement in overall survival for patients with SCCHN has been unfortunately linked specifically to the increased incidence of human papillomavirus (HPV)-related oropharyngeal carcinomas rather than early intervention or detection of disease. The high prevalence of HPV-related oral infection and the increase in HPV-related cancers call for chemopreventive measures to these malignancies.</p><p>HPV vaccines are effective in preventing HPV-related malignancies [<a href="#rid128">128-131</a>]. Despite this, the use of these vaccines is relatively limited at the present. The value of HPV vaccination in reducing the risk of oral HPV infection has not been established. </p><p>There has been an interest in exploring whether a "Pap test equivalent" would be useful for early detection of HPV-related oropharyngeal carcinoma. Cytologic abnormalities in addition to the presence of HPV 16 were strong predictors of the occurrence of oropharyngeal carcinoma [<a href="#rid132">132</a>]. There has also been no clear association between HPV infection and cytologic abnormalities in the oral mucosa, raising the question as to whether HPV infection leads to a precancerous lesion that would precede the occurrence of invasive oropharyngeal carcinoma. The problem may also reside in the location rather than the existence of these lesions in HPV positive disease, which if occurring in the lower part of the tonsillar crypts, would pose difficulty in both detection and monitoring [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H3442169528"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for oral cavity cancer</strong> – We recommend oral cavity cancer screening for squamous cell carcinoma of the head and neck (SCCHN) in all patients, including high-risk groups of alcohol and tobacco users. Regular screening reduced mortality from oral cavity cancer in a randomized trial, likely due to detection of early-stage disease. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there an established approach to chemoprevention?</strong> – Despite the advances with surrogate markers in premalignant lesions, which can assess the risk of developing invasive carcinoma, there is no established approach for chemoprevention of SCCHN. (See <a class="local">'Rationale for chemoprevention'</a> above and <a class="local">'Chemoprevention trials'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential targets for chemoprevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Podoplanin expression may be a powerful predictive factor for oral cancer development in patients with leukoplakia and may guide future therapeutic trials in chemoprevention. (See <a class="local">'Surrogate markers and potential target agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Natural compounds, including green tea polyphenon E (PPE), luteolin, resveratrol, and others, are potentially attractive to be further explored as chemopreventive agents since they are components of daily food or beverage and are potentially nontoxic or less toxic compared with synthetic compounds. (See <a class="local">'Natural compounds'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chemopreventive strategies based on known or potential molecular targets are warranted to help prevent the development of both human papillomavirus (HPV)-related and non-HPV-related oropharyngeal carcinoma (ie, tobacco-induced carcinogenesis) in patients with premalignant disease. (See  <a class="medical medical_review" href="/z/d/html/3387.html" rel="external">"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Data are limited on the efficacy of epidermal growth factor receptor (EGFR) inhibitors, such as <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, in SCCHN chemoprevention. (See <a class="local">'Epidermal growth factor receptor inhibition'</a> above.)</p><p></p><p class="headingAnchor" id="H1055378740"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Charles Rudin, MD, PhD, and Shanthi Marur, MD, MBBS, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sidransky D. Molecular genetics of head and neck cancer. Curr Opin Oncol 1995; 7:229.</a></li><li><a class="nounderline abstract_t">Bouvard V, Nethan ST, Singh D, et al. IARC Perspective on Oral Cancer Prevention. N Engl J Med 2022; 387:1999.</a></li><li><a class="nounderline abstract_t">Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963.</a></li><li><a class="nounderline abstract_t">Partridge M, Pateromichelakis S, Phillips E, et al. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000; 60:3893.</a></li><li><a class="nounderline abstract_t">Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6:1702.</a></li><li><a class="nounderline abstract_t">Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989; 17:449.</a></li><li><a class="nounderline abstract_t">Licciardello JT, Spitz MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys 1989; 17:467.</a></li><li><a class="nounderline abstract_t">Jones AS, Morar P, Phillips DE, et al. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995; 75:1343.</a></li><li><a class="nounderline abstract_t">Chung KY, Mukhopadhyay T, Kim J, et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 1993; 53:1676.</a></li><li><a class="nounderline abstract_t">Bedi GC, Westra WH, Gabrielson E, et al. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 1996; 56:2484.</a></li><li><a class="nounderline abstract_t">Partridge M, Pateromichelakis S, Phillips E, et al. Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma. Clin Cancer Res 2001; 7:1860.</a></li><li><a class="nounderline abstract_t">Nees M, Homann N, Discher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993; 53:4189.</a></li><li><a class="nounderline abstract_t">Kensler TW, Spira A, Garber JE, et al. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) 2016; 9:2.</a></li><li><a class="nounderline abstract_t">Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998; 90:1545.</a></li><li><a class="nounderline abstract_t">Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56:2488.</a></li><li><a class="nounderline abstract_t">Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6:357.</a></li><li><a class="nounderline abstract_t">Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2:682.</a></li><li><a class="nounderline abstract_t">Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:3153.</a></li><li><a class="nounderline abstract_t">Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998; 4:13.</a></li><li><a class="nounderline abstract_t">Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:321.</a></li><li><a class="nounderline abstract_t">Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88:1580.</a></li><li><a class="nounderline abstract_t">Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21:4546.</a></li><li><a class="nounderline abstract_t">Shin DM, Voravud N, Ro JY, et al. Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker. J Natl Cancer Inst 1993; 85:971.</a></li><li><a class="nounderline abstract_t">Mutirangura A, Supiyaphun P, Trirekapan S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 1996; 56:3530.</a></li><li><a class="nounderline abstract_t">Xu XC, Ro JY, Lee JS, et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994; 54:3580.</a></li><li><a class="nounderline abstract_t">Almadori G, Bussu F, Galli J, et al. Serum folate and homocysteine levels in head and neck squamous cell carcinoma. Cancer 2002; 94:1006.</a></li><li><a class="nounderline abstract_t">Eleftheriadou A, Chalastras T, Ferekidou E, et al. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. Anticancer Res 2006; 26:2345.</a></li><li><a class="nounderline abstract_t">Rampersaud GC, Kauwell GP, Hutson AD, et al. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am J Clin Nutr 2000; 72:998.</a></li><li><a class="nounderline abstract_t">Galbiatti AL, da Silva LM, Ruiz-Cintra MT, et al. Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk. Eur J Cancer 2012; 48:1525.</a></li><li><a class="nounderline abstract_t">Jaszewski R, Khan A, Sarkar FH, et al. Folic acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines. Am J Physiol 1999; 277:C1142.</a></li><li><a class="nounderline abstract_t">Saba NF, Wang X, Müller S, et al. Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head Neck 2009; 31:475.</a></li><li><a class="nounderline abstract_t">Kawakita D, Matsuo K, Sato F, et al. Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma. Ann Oncol 2012; 23:186.</a></li><li><a class="nounderline abstract_t">Prasad AS, Beck FW, Doerr TD, et al. Nutritional and zinc status of head and neck cancer patients: an interpretive review. J Am Coll Nutr 1998; 17:409.</a></li><li><a class="nounderline abstract_t">Ip C, Dong Y, Ganther HE. New concepts in selenium chemoprevention. Cancer Metastasis Rev 2002; 21:281.</a></li><li><a class="nounderline abstract_t">Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262:5592.</a></li><li><a class="nounderline abstract_t">Kuzumaki T, Kobayashi T, Ishikawa K. Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem Biophys Res Commun 1998; 251:291.</a></li><li><a class="nounderline abstract_t">Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000; 6:4684.</a></li><li><a class="nounderline abstract_t">Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008; 26:354.</a></li><li><a class="nounderline abstract_t">Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005; 365:1927.</a></li><li><a class="nounderline abstract_t">Cheung LC, Ramadas K, Muwonge R, et al. Risk-Based Selection of Individuals for Oral Cancer Screening. J Clin Oncol 2021; 39:663.</a></li><li><a class="nounderline abstract_t">Santana JC, Delgado L, Miranda J, Sánchez M. Oral Cancer Case Finding Program (OCCFP). Oral Oncol 1997; 33:10.</a></li><li><a class="nounderline abstract_t">Sankaranarayanan R. Health care auxiliaries in the detection and prevention of oral cancer. Oral Oncol 1997; 33:149.</a></li><li><a class="nounderline abstract_t">Prout MN, Sidari JN, Witzburg RA, et al. Head and neck cancer screening among 4611 tobacco users older than forty years. Otolaryngol Head Neck Surg 1997; 116:201.</a></li><li><a class="nounderline abstract_t">Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14:97.</a></li><li><a class="nounderline abstract_t">Nunes DN, Kowalski LP, Simpson AJ. Detection of oral and oropharyngeal cancer by microsatellite analysis in mouth washes and lesion brushings. Oral Oncol 2000; 36:525.</a></li><li><a class="nounderline abstract_t">El-Naggar AK, Mao L, Staerkel G, et al. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn 2001; 3:164.</a></li><li><a class="nounderline abstract_t">Wadsworth JT, Somers KD, Stack BC Jr, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004; 130:98.</a></li><li><a class="nounderline abstract_t">Mitchell MF, Hittelman WK, Lotan R, et al. Chemoprevention trials and surrogate end point biomarkers in the cervix. Cancer 1995; 76:1956.</a></li><li><a class="nounderline abstract_t">Saba NF, Goodman M, Ward K, et al. Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. Oncology 2011; 81:12.</a></li><li><a class="nounderline abstract_t">Kreimer AR, Chaturvedi AK. HPV-associated Oropharyngeal Cancers--Are They Preventable? Cancer Prev Res (Phila) 2011; 4:1346.</a></li><li><a class="nounderline abstract_t">Saba NF, Hurwitz SJ, Kono SA, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) 2014; 7:283.</a></li><li><a class="nounderline abstract_t">Shin DM, Zhang H, Saba NF, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013; 19:1244.</a></li><li><a class="nounderline abstract_t">Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:6976.</a></li><li><a class="nounderline abstract_t">Wolf K. Zur vitamin A behandlung der leukoplakien. Arch Klin Exp Dermatol 1957; :206.</a></li><li><a class="nounderline abstract_t">Stich HF, Rosin MP, Hornby AP, et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988; 42:195.</a></li><li><a class="nounderline abstract_t">Stich HF, Hornby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988; 40:93.</a></li><li><a class="nounderline abstract_t">Garewal HS, Meyskens FL Jr, Killen D, et al. Response of oral leukoplakia to beta-carotene. J Clin Oncol 1990; 8:1715.</a></li><li><a class="nounderline abstract_t">Garewal H. Chemoprevention of oral cancer: beta-carotene and vitamin E in leukoplakia. Eur J Cancer Prev 1994; 3:101.</a></li><li><a class="nounderline abstract_t">Toma S, Benso S, Albanese E, et al. Treatment of oral leukoplakia with beta-carotene. Oncology 1992; 49:77.</a></li><li><a class="nounderline abstract_t">Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 1997; 33:231.</a></li><li><a class="nounderline abstract_t">Liede K, Hietanen J, Saxen L, et al. Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers. Oral Dis 1998; 4:78.</a></li><li><a class="nounderline abstract_t">Wright ME, Virtamo J, Hartman AM, et al. Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial. Cancer 2007; 109:891.</a></li><li><a class="nounderline abstract_t">Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315:1501.</a></li><li><a class="nounderline abstract_t">Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328:15.</a></li><li><a class="nounderline abstract_t">Bairati I, Meyer F, Gélinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005; 97:481.</a></li><li><a class="nounderline abstract_t">Jyothirmayi R, Ramadas K, Varghese C, et al. Efficacy of vitamin A in the prevention of loco-regional recurrence and second primaries in head and neck cancer. Eur J Cancer B Oral Oncol 1996; 32B:373.</a></li><li><a class="nounderline abstract_t">van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92:977.</a></li><li><a class="nounderline abstract_t">Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323:795.</a></li><li><a class="nounderline abstract_t">Bhatia AK, Lee JW, Pinto HA, et al. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 2017; 123:4653.</a></li><li><a class="nounderline abstract_t">Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006; 98:441.</a></li><li><a class="nounderline abstract_t">Perry CF, Stevens M, Rabie I, et al. Chemoprevention of head and neck cancer with retinoids: a negative result. Arch Otolaryngol Head Neck Surg 2005; 131:198.</a></li><li><a class="nounderline abstract_t">Khuri FR, Lippman SM, Spitz MR, et al. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997; 89:199.</a></li><li><a class="nounderline abstract_t">Koch HF. Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid. J Maxillofac Surg 1978; 6:59.</a></li><li class="breakAll">Effect of retinoids on precancerous lesions of oral mucosa. In: Retinoids: Advances in Basic Research and Therapy, Spring-Verlag, Berlin 1981. p.273.</li><li><a class="nounderline abstract_t">Smith W, Saba N. Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol 2005; 55:143.</a></li><li><a class="nounderline abstract_t">Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332:1405.</a></li><li><a class="nounderline abstract_t">Shin DM, Xu XC, Lippman SM, et al. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 1997; 3:875.</a></li><li><a class="nounderline abstract_t">Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 1998; 58:5551.</a></li><li><a class="nounderline abstract_t">Soriano AF, Helfrich B, Chan DC, et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999; 59:6178.</a></li><li><a class="nounderline abstract_t">Renkonen J, Wolff H, Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 2002; 440:594.</a></li><li><a class="nounderline abstract_t">Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 2002; 112:839.</a></li><li><a class="nounderline abstract_t">Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001; 61:1451.</a></li><li><a class="nounderline abstract_t">Jayaprakash V, Rigual NR, Moysich KB, et al. Chemoprevention of head and neck cancer with aspirin: a case-control study. Arch Otolaryngol Head Neck Surg 2006; 132:1231.</a></li><li><a class="nounderline abstract_t">Friis S, Poulsen A, Pedersen L, et al. Use of nonsteroidal anti-inflammatory drugs and risk of oral cancer: a cohort study. Br J Cancer 2006; 95:363.</a></li><li><a class="nounderline abstract_t">Sudbø J, Lee JJ, Lippman SM, et al. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet 2005; 366:1359.</a></li><li><a class="nounderline abstract_t">Curfman GD, Morrissey S, Drazen JM. Retraction: Sudbø J et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004;350:1405-13. N Engl J Med 2006; 355:1927.</a></li><li><a class="nounderline abstract_t">Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10:1565.</a></li><li><a class="nounderline abstract_t">Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55:115.</a></li><li><a class="nounderline abstract_t">Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4:431.</a></li><li><a class="nounderline abstract_t">Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254.</a></li><li><a class="nounderline abstract_t">Cohen EG, Almahmeed T, Du B, et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res 2003; 9:3425.</a></li><li><a class="nounderline abstract_t">Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59:991.</a></li><li><a class="nounderline abstract_t">Chen Z, Zhang X, Li M, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10:5930.</a></li><li><a class="nounderline abstract_t">Saba NF, Choi M, Muller S, et al. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila) 2009; 2:823.</a></li><li><a class="nounderline abstract_t">Nathan CO, Leskov IL, Lin M, et al. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001; 92:1888.</a></li><li><a class="nounderline abstract_t">Ondrey FG, Juhn SK, Adams GL. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996; 106:129.</a></li><li><a class="nounderline abstract_t">Scioscia KA, Snyderman CH, Rueger R, et al. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs. Am J Otolaryngol 1997; 18:1.</a></li><li><a class="nounderline abstract_t">Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981; 107:658.</a></li><li><a class="nounderline abstract_t">Wirth LJ, Krane JF, Li Y, et al. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila) 2008; 1:339.</a></li><li><a class="nounderline abstract_t">Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114:1028.</a></li><li><a class="nounderline abstract_t">Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092.</a></li><li><a class="nounderline abstract_t">Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78:1284.</a></li><li><a class="nounderline abstract_t">Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515.</a></li><li><a class="nounderline abstract_t">Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13:3.</a></li><li><a class="nounderline abstract_t">Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res 1988; 48:6753.</a></li><li><a class="nounderline abstract_t">Califano JA, Ferris RL, Epstein JB, et al. A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract. J Clin Oncol 2012; 30; 15S.</a></li><li><a class="nounderline abstract_t">William WN Jr, Papadimitrakopoulou V, Lee JJ, et al. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol 2016; 2:209.</a></li><li class="breakAll">William WN, Lee WC, Lee JJ, et al. Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). J Clin Oncol 2019; 37:(abstr 6009). Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6009 (Accessed on October 18, 2019).</li><li><a class="nounderline abstract_t">Zhang X, Chen ZG, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005; 11:6261.</a></li><li><a class="nounderline abstract_t">Choe MS, Zhang X, Shin HJ, et al. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005; 4:1448.</a></li><li><a class="nounderline abstract_t">Sun ZJ, Zhang L, Hall B, et al. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 2012; 18:5304.</a></li><li><a class="nounderline abstract_t">Schwartz JL, Baker V, Larios E, Chung FL. Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res 2005; 49:43.</a></li><li><a class="nounderline abstract_t">Seeram NP, Adams LS, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005; 16:360.</a></li><li><a class="nounderline abstract_t">Saba NF, Haigentz M Jr, Vermorken JB, et al. Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention". Oral Oncol 2015; 51:112.</a></li><li><a class="nounderline abstract_t">Negri E, Franceschi S, Bosetti C, et al. Selected micronutrients and oral and pharyngeal cancer. Int J Cancer 2000; 86:122.</a></li><li><a class="nounderline abstract_t">Agarwal R, Mukhtar H. Cancer chemoprevention by polyphenols in green tea and artichoke. Adv Exp Med Biol 1996; 401:35.</a></li><li><a class="nounderline abstract_t">Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993; 85:1038.</a></li><li class="breakAll">Shin DM, Beitler JJ, El-Deiry M, et al. Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck. J Clin Oncol 2019; 37:(abstr 6049). Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6049 (Accessed on October 18, 2019).</li><li><a class="nounderline abstract_t">Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009; 2:931.</a></li><li><a class="nounderline abstract_t">Shin DM, Nannapaneni S, Patel MR, et al. Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. Clin Cancer Res 2020; 26:5860.</a></li><li><a class="nounderline abstract_t">Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) 2010; 3:900.</a></li><li><a class="nounderline abstract_t">Amin AR, Khuri FR, Chen ZG, Shin DM. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res (Phila) 2009; 2:538.</a></li><li><a class="nounderline abstract_t">Haque A, Rahman MA, Chen ZG, et al. Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. Apoptosis 2015; 20:986.</a></li><li><a class="nounderline abstract_t">Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73:1733.</a></li><li><a class="nounderline abstract_t">Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243:934.</a></li><li><a class="nounderline abstract_t">Rampias T, Sasaki C, Psyrri A. Molecular mechanisms of HPV induced carcinogenesis in head and neck. Oral Oncol 2014; 50:356.</a></li><li><a class="nounderline abstract_t">Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307:693.</a></li><li><a class="nounderline abstract_t">Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113:3036.</a></li><li><a class="nounderline abstract_t">Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401.</a></li><li><a class="nounderline abstract_t">FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915.</a></li><li><a class="nounderline abstract_t">Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301.</a></li><li><a class="nounderline abstract_t">Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) 2011; 4:1378.</a></li></ol></div><div id="topicVersionRevision">Topic 3391 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7654824" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Molecular genetics of head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36378601" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : IARC Perspective on Oral Cancer Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13094644" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10919665" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815888" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Predicting cancer development in oral leukoplakia: ten years of translational research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2674073" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2674075" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7882285" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Second primary tumors in patients with head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8453641" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8653681" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Multiple head and neck tumors: evidence for a common clonal origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11448897" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8364914" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26744449" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Transforming Cancer Prevention through Precision Medicine and Immune-oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790547" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8653682" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetic progression model for head and neck cancer: implications for field cancerization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690511" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640560" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205534" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516947" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8275461" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8901856" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597742" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098774" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8758922" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8012985" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920469" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serum folate and homocysteine levels in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16821614" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11010943" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Genomic DNA methylation decreases in response to moderate folate depletion in elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22051736" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10600765" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Folic acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19072997" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460376" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9791836" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nutritional and zinc status of head and neck cancer patients: an interpretive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12549766" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : New concepts in selenium chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3106339" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Genistein, a specific inhibitor of tyrosine-specific protein kinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790949" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156220" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202409" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936419" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33449824" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk-Based Selection of Individuals for Oral Cancer Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9192546" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Oral Cancer Case Finding Program (OCCFP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307722" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Health care auxiliaries in the detection and prevention of oral cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9051065" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Head and neck cancer screening among 4611 tobacco users older than forty years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172258" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11036246" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Detection of oral and oropharyngeal cancer by microsatellite analysis in mouth washes and lesion brushings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11687600" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14732777" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Identification of patients with head and neck cancer using serum protein profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634987" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chemoprevention trials and surrogate end point biomarkers in the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21912193" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21893495" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : HPV-associated Oropharyngeal Cancers--Are They Preventable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24085777" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23422093" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172459" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Zur vitamin A behandlung der leukoplakien</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3403064" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3370632" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Response of oral leukoplakias to the administration of vitamin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2213107" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Response of oral leukoplakia to beta-carotene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8019381" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Chemoprevention of oral cancer: beta-carotene and vitamin E in leukoplakia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574255" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of oral leukoplakia with beta-carotene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307711" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9680894" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17265529" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3537787" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : 13-cis-retinoic acid in the treatment of oral leukoplakia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416267" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812073" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039219" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy of vitamin A in the prevention of loco-regional recurrence and second primaries in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861309" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202902" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28786105" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595780" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781758" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Chemoprevention of head and neck cancer with retinoids: a negative result.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017000" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Molecular epidemiology and retinoid chemoprevention of head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/274508" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/274508" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886010" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Retinoids as chemoprevention for head and neck cancer: where do we go from here?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7723796" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815762" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9850093" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10626810" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12070598" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12150615" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11245450" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116820" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Chemoprevention of head and neck cancer with aspirin: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868546" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Use of nonsteroidal anti-inflammatory drugs and risk of oral cancer: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16226613" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17079770" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Retraction: SudbøJ et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270-8 and SudbøJ et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004;350:1405-13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15014005" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16118353" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prostaglandins and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706335" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637389" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12960132" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10070952" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355926" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19737986" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745262" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : COX-2 expression in dysplasia of the head and neck: correlation with elF4E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8583839" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006670" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7295159" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138978" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16943394" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15713943" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8826952" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815714" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1313356" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2460228" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26540028" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26540028" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16144930" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170038" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22859719" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15538715" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Molecular and cellular effects of green tea on oral cells of smokers: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936648" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25434586" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10728605" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Selected micronutrients and oral and pharyngeal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8886125" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cancer chemoprevention by polyphenols in green tea and artichoke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515490" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Tea and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515490" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Tea and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892663" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32943457" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20663981" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Chemoprevention of head and neck cancer with green tea polyphenols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470788" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25860284" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288508" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2537532" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953776" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Molecular mechanisms of HPV induced carcinogenesis in head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282321" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Prevalence of oral HPV infection in the United States, 2009-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18980286" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288094" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494925" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19586656" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21836021" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
